| Literature DB >> 33430260 |
Giuseppe Cappellano1,2, Davide Raineri1,2, Roberta Rolla1,3, Mara Giordano1,3, Chiara Puricelli3, Beatrice Vilardo1,2, Marcello Manfredi2,4, Vincenzo Cantaluppi2,4,5, Pier Paolo Sainaghi2,4,6, Luigi Castello4,7, Nello De Vita4, Lorenza Scotti4, Rosanna Vaschetto4, Umberto Dianzani1,3, Annalisa Chiocchetti1,2.
Abstract
Sars-Cov-2 infection causes fever and cough that may rapidly lead to acute respiratory distress syndrome (ARDS). Few biomarkers have been identified but, unfortunately, these are individually poorly specific, and novel biomarkers are needed to better predict patient outcome. The aim of this study was to evaluate the diagnostic performance of circulating platelets (PLT)-derived extracellular vesicles (EVs) as biomarkers for Sars-Cov-2 infection, by setting a rapid and reliable test on unmanipulated blood samples. PLT-EVs were quantified by flow cytometry on two independent cohorts of Sars-CoV-2+ (n = 69), Sars-Cov-2- (n = 62) hospitalized patients, and healthy controls. Diagnostic performance of PLT-EVs was evaluated by receiver operating characteristic (ROC) curve. PLT-EVs count were higher in Sars-Cov-2+ compared to Sars-Cov-2- patients or HC. ROC analysis of the combined cohorts showed an AUC = 0.79 and an optimal cut-off value of 1472 EVs/μL, with 75% sensitivity and 74% specificity. These data suggest that PLT-EVs might be an interesting biomarker deserving further investigations to test their predictive power.Entities:
Keywords: COVID-19; Sars-Cov-2; circulating biomarker; extracellular vesicles; platelets
Mesh:
Substances:
Year: 2021 PMID: 33430260 PMCID: PMC7825711 DOI: 10.3390/cells10010085
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600